US Stock Market Move | Q3 innovative drug revenue up 33% year-over-year; Teva Pharmaceutical Industries Limited Sponsored ADR (TEVA.US) rises over 4%.

On Tuesday, Teva Pharmaceutical Industries Limited Sponsored ADR (TEVA.US) rose over 4% to $42.65, hitting an all-time high. On the news front, Teva Pharmaceutical Industries Limited Sponsored ADR reported its Q3 2026 financial results, with non-GAAP earnings per share of $0.86, beating market expectations by $0.14; revenue of $4.4 billion, down 2% year-over-year, beating market expectations by $170 million. Innovative drugs AUSTEDO, AJOVY, and UZEDY together achieved approximately $1.1 billion in revenue, up 33% year-over-year on a constant currency basis, and Teva raised its full-year 2026 revenue outlook for these three brands. By product, on a constant currency basis, AUSTEDO revenue grew 21% year-over-year to $751 million; AJOVY revenue grew 61% to $269 million; UZEDY revenue grew 96% to $85 million. Excluding the $500 million duvakitug milestone payment in Q4 2025, non-GAAP gross margin expanded 345 basis points year-over-year to 58.7%, a ten-year quarterly high. The company disclosed its fiscal 2026 guidance: revenue of $16.7-17.0 billion, versus the consensus estimate of $16.66 billion; non-GAAP diluted earnings per share of $1.92-2.11, versus the consensus estimate of $2.09; adjusted EBITDA of $4.23-4.43 billion; free cash flow of $2.1-2.4 billion.